Search

Your search keyword '"Calverley, Peter"' showing total 449 results
Start Over Author "Calverley, Peter" Search Limiters Peer Reviewed
449 results on '"Calverley, Peter"'

3. Machine Learning and Prediction of All-Cause Mortality in COPD

Author

Moll, Matthew, Qiao, Dandi, Regan, Elizabeth A., Hunninghake, Gary M., Make, Barry J., Tal-Singer, Ruth, McGeachie, Michael.J., Castaldi, Peter J., San Jose Estepar, Raul, Washko, George R., Wells, James M., LaFon, David, Strand, Matthew, Bowler, Russell P., Han, MeiLan.K., Vestbo, Jorgen, Celli, Bartolome, Calverley, Peter, Crapo, James, Silverman, Edwin K., Hobbs, Brian D., and Cho, Michael H.

Published
2020
Full Text
View/download PDF

4. Continuous positive airway pressure versus standard care for the treatment of people with mild obstructive sleep apnoea (MERGE): a multicentre, randomised controlled trial

Author

Wimms, Alison J, Kelly, Julia L, Turnbull, Christopher D, McMillan, Alison, Craig, Sonya E, O'Reilly, John F, Nickol, Annabel H, West, Sophie D, Simonds, Anita K, Withana, Shirmila, Pepperell, Justin CT, Ward, Neil R, Kent, Brian D, Quinnell, Timothy, Paracha, Mohammad, Anderson, William, Hedley, Emma L, Decker, Meredith D, Willes, Leslee A, Calverley, Peter M A, Benjafield, Adam V, Stradling, John R, and Morrell, Mary J

Published
2020
Full Text
View/download PDF

15. Prevalence, Diagnostic Utility and Associated Characteristics of Bronchodilator Responsiveness.

Author

Beasley, Richard, Hughes, Rod, Agusti, Alvar, Calverley, Peter, Chipps, Bradley, del Olmo, Ricardo, Papi, Alberto, Price, David, Reddel, Helen, Müllerová, Hana, and Rapsomaniki, Eleni

Abstract

Rationale: The prevalence and diagnostic utility of bronchodilator responsiveness (BDR) in a real-life setting is unclear. Objective: To explore this uncertainty in patients aged ⩾12 years with physician-assigned diagnoses of asthma, asthma and chronic obstructive pulmonary disease (COPD), or COPD in NOVELTY, a prospective cohort study in primary and secondary care in 18 countries. Methods: The proportion of patients with a positive BDR test in each diagnostic category was calculated using 2005 (ΔFEV1 or ΔFVC ⩾12% and ⩾200 ml) and 2021 (ΔFEV1 or ΔFVC >10% predicted) European Respiratory Society/American Thoracic Society criteria. Measurements and Main Results: We studied 3,519 patients with a physician-assigned diagnosis of asthma, 833 with a diagnosis of asthma + COPD, and 2,436 with a diagnosis of COPD. The prevalence of BDR was 19.7% (asthma), 29.6% (asthma + COPD), and 24.7% (COPD) using 2005 criteria and 18.1%, 23.3%, and 18.0%, respectively, using 2021 criteria. Using 2021 criteria in patients diagnosed with asthma, BDR was associated with higher fractional exhaled nitric oxide; lower lung function; higher symptom burden; more frequent hospital admissions; and greater use of triple therapy, oral corticosteroids, or biologics. In patients diagnosed with COPD, BDR (2021) was associated with lower lung function and higher symptom burden. Conclusions: BDR prevalence in patients with chronic airway diseases receiving treatment ranges from 18% to 30%, being modestly lower with the 2021 than with the 2005 European Respiratory Society/American Thoracic Society criteria, and it is associated with lower lung function and greater symptom burden. These observations question the validity of BDR as a key diagnostic tool for asthma managed in clinical practice or as a standard inclusion criterion for clinical trials of asthma and instead suggest that BDR be considered a treatable trait for chronic airway disease. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. Determinants of exercise-induced oxygen desaturation including pulmonary emphysema in COPD: Results from the ECLIPSE study

Author

Andrianopoulos, Vasileios, Celli, Bartolome R., Franssen, Frits M.E., Pinto-Plata, Victor M., Calverley, Peter M.A., Vanfleteren, Lowie E.G.W., Vogiatzis, Ioannis, Vestbo, Jørgen, Agusti, Alvar, Bakke, Per S., Rennard, Stephen I., MacNee, William, Tal-Singer, Ruth, Yates, Julie C., Wouters, Emiel F.M., and Spruit, Martijn A.

Published
2016
Full Text
View/download PDF

21. A Double-Blind, Randomized, Placebo-controlled Trial of Long-Term Doxycycline Therapy on Exacerbation Rate in Patients with Stable Chronic Obstructive Pulmonary Disease.

Author

Allinson, James P., Vlies, Ben H., Brill, Simon E., Law, Martin, Burnside, Girvan, Finney, Lydia J., Alves-Moreira, Luana, Donaldson, Gavin C., Calverley, Peter M. A., Walker, Paul P., and Wedzicha, Jadwiga A.

Subjects
CHRONIC obstructive pulmonary disease, DOXYCYCLINE, DISEASE exacerbation
Abstract

Rationale: Chronic obstructive pulmonary disease (COPD) exacerbations are a major cause of morbidity and mortality, and preventing them is a key treatment target. Long-term macrolide treatment is effective at reducing exacerbations, but there is a paucity of evidence for other antibiotic classes. Objectives: To assess whether 12-month use of doxycycline reduces the exacerbation rate in people with COPD. Methods: People with moderate to very severe COPD and an exacerbation history were recruited from three UK centers and randomized to 12 months of doxycycline 100 mg once daily or placebo. The primary study outcome was the exacerbation rate per person-year. Results: A total of 222 people were randomized. Baseline mean FEV1 was 1.35 L (SD, 0.35 L), 52.5% predicted (SD, 15.9% predicted). The median number of treated exacerbations in the year before the study was 2 (SD, 1-4). A total of 71% of patients reported two or more exacerbations, and 81% were already prescribed inhaled corticosteroids at baseline. The COPD exacerbation rate did not differ between the groups (doxycycline/placebo rate ratio [RR], 0.86; 95% confidence interval [CI], 0.67-1.10; P = 0.23). No difference was seen if only treated exacerbations or hospitalizations were considered. In preplanned subgroup analysis, doxycycline appeared to better reduce the exacerbation rate among people with severe COPD (RR, 0.36; 95% CI, 0.15-0.85; P = 0.019) and in those with an eosinophil count, 300 cells/μl (RR, 0.50; 95% CI, 0.29-0.84; P = 0.01). Health statusmeasured by St. George's Respiratory Questionnaire was 5.2 points worse in the doxycycline group at 12months (P,0.007). Conclusions: Doxycycline did not significantly reduce the exacerbation rate, over 12 months, in participants with COPD who exacerbated regularly, but it may have benefitted those with more severe COPD or blood eosinophil counts ,300 cells/μl. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

35. Contemporary Concise Review 2022: Chronic obstructive pulmonary disease.

Author

Calverley, Peter M. A. and Walker, Paul P.

Subjects
*CHRONIC obstructive pulmonary disease, *BRONCHIECTASIS, *CORONARY artery calcification
Abstract

SUMMARY OF KEY POINTS: International respiratory organizations now recommend using lower limit of normal and standardized residuals to diagnose airflow obstruction and COPD though using a fixed ratio <0.7 is simpler and robustly predicts important clinical outcomes.The most common COPD comorbidities are coronary artery calcification, emphysema and bronchiectasis. COPD patients with psychological (high anxiety and depression) and cachectic (underweight and osteoporotic) comorbidity have higher mortality and exacerbate more.Serum eosinophil count remains an important COPD biomarker and we have greater clarity about normal eosinophil levels in COPD and the wider population.Criteria for entry into COPD clinical trials continue to exclude many patients, in particular those at greater risk of exacerbation and death.The effect of hyperinflation on cardiac function impacts COPD mortality and is an important target for successful lung volume reduction procedures. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

41. α;1-Antitrypsin Protease Inhibitor MZ Heterozygosity Is Associated With Airflow Obstruction in Two Large Cohorts

Author

Sørheim, Inga-Cecilie, Bakke, Per, Gulsvik, Amund, Pillai, Sreekumar G., Johannessen, Ane, Gaarder, Per I., Campbell, Edward J., Agustí, Alvar, Calverley, Peter M.A., Donner, Claudio F., Make, Barry J., Rennard, Stephen I., Vestbo, Jørgen, Wouters, Emiel F.M., Paré, Peter D., Levy, Robert D., Coxson, Harvey O., Lomas, David A., Hersh, Craig P., and Silverman, Edwin K.

Published
2010
Full Text
View/download PDF

46. One-year change in health status and subsequent outcomes in COPD

Author

Wilke, Sarah, Jones, Paul W, Müllerova, H, Vestbo, Jørgen, Tal-Singer, Ruth, Franssen, Frits ME, Agusti, Alvar, Bakke, Per, Calverley, Peter M, Coxson, Harvey O, Crim, Courtney, Edwards, Lisa D, Lomas, David A, MacNee, William, Rennard, Stephen I, Yates, Julie C, Wouters, Emiel FM, and Spruit, Martijn A

Published
2015
Full Text
View/download PDF

47. Hospitalized Exacerbations of COPD: Risk Factors and Outcomes in the ECLIPSE Cohort

Author

Müllerova, Hana, Maselli, Diego J., Locantore, Nicholas, Vestbo, Jørgen, Hurst, John R., Wedzicha, Jadwiga A., Bakke, Per, Agusti, Alvar, Anzueto, Antonio, Ivanov, Yavor, Kostov, Kosta, Bourbeau, Jean, Fitzgerald, Mark, Hernández, Paul, Killian, Kieran, Levy, Robert, Maltais, Francois, O´Donnell, Denis, Krepelka, Jan, Vestbo, Jørgen, Wouters, Emiel F. M., Quinn, Dean, Bakke, Per, Kosnik, Mitja, Agusti, Alvar, Feschenko, Yuri, Gavrisyuk, Volodymyr, Yashina, Lyudmila, MacNee, William, Singh, S. David, Wedzicha, Jadwiga, Anzueto, Antonio, Braman, Sidney, Casaburi, Richard, Celli, Bart, Giessel, Glenn, Gotfried, Mark, Greenwald, Gary, Hanania, Nicola, Mahler, Don, Make, Barry, Rennard, Stephen, Rochester, Carolyn, Scanlon, Paul, Schuller, Dan, Sciurba, Frank, Sharafkhaneh, Amir, Siler, Thomas, Silverman, Edwin, Wanner, Adam, Wise, Robert, Zu Wallack, Richard, Bakke, Per, Coxson, Harvey, Edwards, Lisa, Lomas, David, MacNee, William, Silverman, Edwin, Tal-Singer, Ruth, Vestbo, Jørgen, Yates, Julie, Agusti, Alvar, Calverley, Peter, Celli, Bartolome, Crim, Courtney, Miller, Bruce, MacNee, William, Rennard, Stephen, Tal-Singer, Ruth, and Wouters, Emiel

Published
2015
Full Text
View/download PDF

48. An Official American Thoracic Society/European Respiratory Society Statement: Research Questions in Chronic Obstructive Pulmonary Disease

Author

Celli, Bartolome R., Decramer, Marc, Wedzicha, Jadwiga A., Wilson, Kevin C., Agustí, Alvar, Criner, Gerard J., MacNee, William, Make, Barry J., Rennard, Stephen I., Stockley, Robert A., Vogelmeier, Claus, Anzueto, Antonio, Au, David H., Barnes, Peter J., Burgel, Pierre-Regis, Calverley, Peter M., Casanova, Ciro, Clini, Enrico M., Cooper, Christopher B., Coxson, Harvey O., Dusser, Daniel J., Fabbri, Leonardo M., Fahy, Bonnie, Ferguson, Gary T., Fisher, Andrew, Fletcher, Monica J., Hayot, Maurice, Hurst, John R., Jones, Paul W., Mahler, Donald A., Maltais, François, Mannino, David M., Martinez, Fernando J., Miravitlles, Marc, Meek, Paula M., Papi, Alberto, Rabe, Klaus F., Roche, Nicolas, Sciurba, Frank C., Sethi, Sanjay, Siafakas, Nikos, Sin, Don D., Soriano, Joan B., Stoller, James K., Tashkin, Donald P., Troosters, Thierry, Verleden, Geert M., Verschakelen, Johny, Vestbo, Jorgen, Walsh, John W., Washko, George R., Wise, Robert A., Wouters, Emiel F. M., and ZuWallack, Richard L.

Published
2015
Full Text
View/download PDF

49. Identification of Five Chronic Obstructive Pulmonary Disease Subgroups with Different Prognoses in the ECLIPSE Cohort Using Cluster Analysis

Author

Rennard, Stephen I., Locantore, Nicholas, Delafont, Bruno, Tal-Singer, Ruth, Silverman, Edwin K., Vestbo, Jørgen, Miller, Bruce E., Bakke, Per, Celli, Bartolomé, Calverley, Peter M. A., Coxson, Harvey, Crim, Courtney, Edwards, Lisa D., Lomas, David A., MacNee, William, Wouters, Emiel F. M., Yates, Julie C., Coca, Ignacio, and Agustí, Alvar

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results